A systematic study of dysregulated MicroRNA in type 2 diabetes mellitus

International Journal of Molecular Sciences

Volumn 18, Issue 3, 2017, Pages

  He, Yuqing ^a   Ding, Yuanlin ^a   Liang, Biyu ^a   Lin, Juanjuan ^a   Kim, Taek Kyun ^b   Yu, Haibing ^a   Hang, Hanwei ^a   Wang, Kai ^b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

Author keywords

MicroRNA; MiRNA mRNA interaction network; Systematic study; Type 2 diabetes mellitus

Indexed keywords

MICRORNA; MESSENGER RNA; TRANSCRIPTOME;

ARTICLE; CARBOHYDRATE METABOLISM; GENE EXPRESSION; HUMAN; LIPID METABOLISM; MICROARRAY ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; TRANSCRIPTION REGULATION; ANTIBODY SPECIFICITY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; META ANALYSIS; METABOLISM; RNA INTERFERENCE;

DIABETES MELLITUS, TYPE 2; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORKS; HUMANS; MICRORNAS; ORGAN SPECIFICITY; RNA INTERFERENCE; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTOME;

EID: 85014239584     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18030456     Document Type: Article

References (111)

1. Rogers, E.A.; Fine, S.; Handley, M.A.; Davis, H.; Kass, J.; Schillinger, D. Development and early implementation of the bigger picture, a youth-targeted public health literacy campaign to prevent type 2 diabetes. J. Health Commun. 2014, 19, 144-160. [CrossRef] [PubMed]
2. Jin, W.; Patti, M. Genetic determinants and molecular pathways in the pathogenesis of type 2 diabetes. Clin. Sci. 2009, 116, 99-111. [CrossRef] [PubMed]
3. Ribbing, J.; Hamrén, B.; Svensson, M.K.; Karlsson, M.O. A model for glucose, insulin, and β-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. J. Clin. Pharmacol. 2010, 50, 861-872. [CrossRef] [PubMed]
4. Pedicino, D.; Liuzzo, G.; Trotta, F.; Giglio, A.F.; Giubilato, S.; Martini, F.; Zaccardi, F.; Scavone, G.; Previtero, M.; Massaro, G. Adaptive immunity, inflammation, and cardiovascular complications in type 1 and type 2 diabetes mellitus. J. Diabetes Res. 2013, 2013, 184258. [CrossRef] [PubMed]
5. Bello, N.A.; Pfeffer, M.A.; Skali, H.; McGill, J.B.; Rossert, J.; Olson, K.A.; Weinrauch, L.; Cooper, M.E.; de Zeeuw, D.; Rossing, P. Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. BMJ Open Diabetes Res. Care 2014, 2, e000011. [CrossRef] [PubMed]
6. Paneni, F.; Beckman, J.A.; Creager, M.A.; Cosentino, F. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Eur. Heart J. 2013, 34, 2436-2443. [CrossRef] [PubMed]
7. Shlomai, G.; Neel, B.; LeRoith, D.; Gallagher, E.J. Type 2 diabetes mellitus and cancer: The role of pharmacotherapy. J. Clin. Oncol. 2016, 34, 4261-4269. [PubMed]
8. Klil-Drori, A.J.; Azoulay, L.; Pollak, M.N. Cancer, obesity, diabetes, and antidiabetic drugs: Is the fog clearing? Nat. Rev. Clin. Oncol. 2017, 14, 85-99. [CrossRef] [PubMed]
9. Liu, H.T.; Xu, Y.T.; Li, H.Y.; Zhao, J.; Zhai, H.Y.; Chen, Y. Loss of microRNA-145 expression is involved in the development and prognosis of breast cancer complicated by type 2 diabetes mellitus. Int. J. Biol. Markers 2016, 31, e368-e374. [CrossRef] [PubMed]
10. Wang, Y.; Wang, B.; Yan, S.; Shen, F.; Cao, H.; Fan, J.; Zhang, R.; Gu, J. Type 2 diabetes and gender differences in liver cancer by considering different confounding factors: A meta-analysis of cohort studies. Ann. Epidemiol. 2016, 26, 764-772. [CrossRef] [PubMed]
11. Sayyid, R.K.; Fleshner, N.E. Diabetes mellitus type 2: A driving force for urological complications. Trends Endocrinol. Metab. 2016, 27, 249-261. [CrossRef] [PubMed]
12. Esteller, M. Non-coding RNAs in human disease. Nat. Rev. Genet. 2011, 12, 861-874. [CrossRef] [PubMed]
13. Kellis, M.; Wold, B.; Snyder, M.P.; Bernstein, B.E.; Kundaje, A.; Marinov, G.K.; Ward, L.D.; Birney, E.; Crawford, G.E.; Dekker, J. Defining functional DNA elements in the human genome. Proc. Natl. Acad. Sci. USA 2014, 111, 6131-6138. [CrossRef] [PubMed]
14. Eliasson, L.; Esguerra, J.L.S. Role of non-coding RNAs in pancreatic β-cell development and physiology. Acta Physiol. 2014, 211, 273-284. [CrossRef] [PubMed]
15. Lee, M.J.; Park, D.H.; Kang, J.H. Exosomes as the source of biomarkers of metabolic diseases. Ann. Pediatr. Endocrinol. Metab. 2016, 21, 119-125. [CrossRef] [PubMed]
16. Simpson, K.; Wonnacott, A.; Fraser, D.J.; Bowen, T. MicroRNAs in diabetic nephropathy: From biomarkers to therapy. Curr. Diabetes Rep. 2016, 16, 35. [CrossRef] [PubMed]
17. Deiuliis, J.A. MicroRNAs as regulators of metabolic disease: Pathophysiologic significance and emerging role as biomarkers and therapeutics. Int. J. Obes. 2016, 40, 88-101. [CrossRef] [PubMed]
18. Kato, M.; Natarajan, R. MicroRNAs in diabetic nephropathy: Functions, biomarkers, and therapeutic targets. Ann. N. Y. Acad. Sci. 2015, 1353, 72-88. [CrossRef] [PubMed]
19. Price, N.L.; Ramirez, C.M.; Fernandez-Hernando, C. Relevance of microRNA in metabolic diseases. Crit. Rev. Clin. Lab. Sci. 2014, 51, 305-320. [CrossRef] [PubMed]
20. Chen, H.; Lan, H.Y.; Roukos, D.H.; Cho, W.C. Application of microRNAs in diabetes mellitus. J. Endocrinol. 2014, 222, 1-10. [CrossRef] [PubMed]
21. Fernandez-Hernando, C.; Ramirez, C.M.; Goedeke, L.; Suarez, Y. MicroRNAs in metabolic disease. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 178-185. [CrossRef] [PubMed]
22. Guay, C.; Roggli, E.; Nesca, V.; Jacovetti, C.; Regazzi, R. Diabetes mellitus, a microRNA-related disease? Transl. Res. 2011, 157, 253-264. [CrossRef] [PubMed]
23. Kameswaran, V.; Bramswig, N.C.; McKenna, L.B.; Penn, M.; Schug, J.; Hand, N.J.; Chen, Y.; Choi, I.; Vourekas, A.; Won, K.-J. Epigenetic regulation of the DLK1-MEG3 microRNA cluster in human type 2 diabetic islets. Cell Metab. 2014, 19, 135-145. [CrossRef] [PubMed]
24. Balasubramanyam, M.; Aravind, S.; Gokulakrishnan, K.; Prabu, P.; Sathishkumar, C.; Ranjani, H.; Mohan, V. Impaired miR-146a expression links subclinical inflammation and insulin resistance in type 2 diabetes. Mol. Cell. Biochem. 2011, 351, 197-205. [CrossRef] [PubMed]
25. Caporali, A.; Meloni, M.; Vollenkle, C.; Bonci, D.; Sala-Newby, G.B.; Addis, R.; Spinetti, G.; Losa, S.; Masson, R.; Baker, A.H.; et al. Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 2011, 123, 282-291. [CrossRef] [PubMed]
26. Karolina, D.S.; Armugam, A.; Tavintharan, S.; Wong, M.T.; Lim, S.C.; Sum, C.F.; Jeyaseelan, K. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS ONE 2011, 6, e22839. [CrossRef]
27. Karolina, D.S.; Tavintharan, S.; Armugam, A.; Sepramaniam, S.; Pek, S.L.; Wong, M.T.; Lim, S.C.; Sum, C.F.; Jeyaseelan, K. Circulating miRNA profiles in patients with metabolic syndrome. J. Clin. Endocrinol. Metab. 2012, 97, E2271-E2276. [CrossRef] [PubMed]
28. Meng, S.; Cao, J.T.; Zhang, B.; Zhou, Q.; Shen, C.X.; Wang, C.Q. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J. Mol. Cell. Cardiol. 2012, 53, 64-72. [CrossRef] [PubMed]
29. Ortega, F.J.; Moreno-Navarrete, J.M.; Pardo, G.; Sabater, M.; Hummel, M.; Ferrer, A.; Rodriguez-Hermosa, J.I.; Ruiz, B.; Ricart, W.; Peral, B. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS ONE 2010, 5, e9022. [CrossRef] [PubMed]
30. Zampetaki, A.; Kiechl, S.; Drozdov, I.; Willeit, P.; Mayr, U.; Prokopi, M.; Mayr, A.; Weger, S.; Oberhollenzer, F.; Bonora, E.; et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circul. Res. 2010, 107, 810-817. [CrossRef] [PubMed]
31. Zhao, H.; Guan, J.; Lee, H.-M.; Sui, Y.; He, L.; Siu, J.J.; Patty, P.; Tong, P.C.; Lai, F.M.; Chan, J.C. Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through β-cell deficit and islet amyloid deposition. Pancreas 2010, 39, 843-846. [CrossRef] [PubMed]
32. Baldeon Rojas, L.; Weigelt, K.; de Wit, H.; Ozcan, B.; van Oudenaren, A.; Sempertegui, F.; Sijbrands, E.; Grosse, L.; Freire, W.; Drexhage, H.A.; et al. Decreased serum level of miR-146a as sign of chronic inflammation in type 2 diabetic patients. PLoS ONE 2014, 9, e115209.
33. Granjon, A.; Gustin, M.P.; Rieusset, J.; Lefai, E.; Meugnier, E.; Guller, I.; Cerutti, C.; Paultre, C.; Disse, E.; Rabasa-Lhoret, R.; et al. The microRNA signature in response to insulin reveals its implication in the transcriptional action of insulin in human skeletal muscle and the role of a sterol regulatory element-binding protein-1C/myocyte enhancer factor 2C pathway. Diabetes 2009, 58, 2555-2564. [CrossRef] [PubMed]
34. Kong, L.; Zhu, J.; Han, W.; Jiang, X.; Xu, M.; Zhao, Y.; Dong, Q.; Pang, Z.; Guan, Q.; Gao, L.; et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: A clinical study. Acta Diabetol. 2011, 48, 61-69. [CrossRef] [PubMed]
35. Mao, G.; Liu, L. MicroRNA-18a is a genetic marker for the early diagnosis of cerebral injury induced by type 2 diabetes. Exp. Ther. Med. 2014, 8, 1901-1905. [CrossRef] [PubMed]
36. Locke, J.; da Silva Xavier, G.; Dawe, H.; Rutter, G.; Harries, L. Increased expression of miR-187 in human islets from individuals with type 2 diabetes is associated with reduced glucose-stimulated insulin secretion. Diabetologia 2014, 57, 122-128. [CrossRef] [PubMed]
37. Ren, Y.H.; Shi, X.X.; Yan, D.D.; Li, X.L. The change of expression level of circulating miRNA-126 in patients with type 2 diabetes and its relative factors. Clin. J. Diabetes 2014, 22, 633-636.
38. Santovito, D.; De Nardis, V.; Marcantonio, P.; Mandolini, C.; Paganelli, C.; Vitale, E.; Buttitta, F.; Bucci, M.; Mezzetti, A.; Consoli, A.; et al. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: Effect of glycemic control. J. Clin. Endocrinol. Metab. 2014, 99, 1681-1685. [CrossRef] [PubMed]
39. Sun, K.; Chang, X.; Yin, L.; Li, J.; Zhou, T.; Zhang, C.; Chen, X. Expression and DNA methylation status of microRNA-375 in patients with type 2 diabetes mellitus. Mol. Med. Rep. 2014, 9, 967-972. [CrossRef] [PubMed]
40. Yang, Z.; Chen, H.; Si, H.; Li, X.; Ding, X.; Sheng, Q.; Chen, P.; Zhang, H. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol. 2014, 51, 823-831. [CrossRef] [PubMed]
41. Zhang, L.Q.; Han, Z.P. Expression and clinical significance of peripheral hsa-miR-29b during the type 2 diabetes. J. Mod. Lab. Med. 2014, 29, 113-116.
42. Agarwal, P.; Srivastava, R.; Srivastava, A.K.; Ali, S.; Datta, M. MiR-135a targets IRS2 and regulates insulin signaling and glucose uptake in the diabetic gastrocnemius skeletal muscle. Biochim. Biophys. Acta 2013, 1832, 1294-1303. [CrossRef] [PubMed]
43. Corral-Fernandez, N.E.; Salgado-Bustamante, M.; Martinez-Leija, M.E.; Cortez-Espinosa, N.; Garcia-Hernandez, M.H.; Reynaga-Hernandez, E.; Quezada-Calvillo, R.; Portales-Perez, D.P. Dysregulated miR-155 expression in peripheral blood mononuclear cells from patients with type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 2013, 121, 347-353. [CrossRef] [PubMed]
44. Jiang, S.Y.; Jiao, J.; Zhang, T.T.; Xu, Y.P. Pharmacokinetics study of recombinant hirudin in the plasma of rats using chromogenic substrate, ELISA, and radioisotope assays. PLoS ONE 2013, 8, e64336. [CrossRef] [PubMed]
45. Pescador, N.; Perez-Barba, M.; Ibarra, J.M.; Corbaton, A.; Martinez-Larrad, M.T.; Serrano-Rios, M. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS ONE 2013, 8, e77251. [CrossRef] [PubMed]
46. Rong, Y.; Bao, W.; Shan, Z.; Liu, J.; Yu, X.; Xia, S.; Gao, H.; Wang, X.; Yao, P.; Hu, F.B.; et al. Increased microRNA-146a levels in plasma of patients with newly diagnosed type 2 diabetes mellitus. PLoS ONE 2013, 8, e73272. [CrossRef] [PubMed]
47. Zhou, J.; Peng, R.; Li, T.; Luo, X.; Peng, H.; Zha, H.; Yin, P.; Wen, L.; Zhang, Z. A potentially functional polymorphism in the regulatory region of let-7a-2 is associated with an increased risk for diabetic nephropathy. Gene 2013, 527, 456-461. [CrossRef] [PubMed]
48. Liu, Y.; Gao, G.; Yang, C.; Zhou, K.; Shen, B.; Liang, H.; Jiang, X. The role of circulating microRNA-126 (miR-126): A novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. Int. J. Mol. Sci. 2014, 15, 10567-10577. [CrossRef] [PubMed]
49. Gallagher, I.J.; Scheele, C.; Keller, P.; Nielsen, A.R.; Remenyi, J.; Fischer, C.P.; Roder, K.; Babraj, J.; Wahlestedt, C.; Hutvagner, G. Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Med. 2010, 2, 9. [CrossRef] [PubMed]
50. Klöting, N.; Berthold, S.; Kovacs, P.; Schön, M.R.; Fasshauer, M.; Ruschke, K.; Stumvoll, M.; Blüher, M. MicroRNA expression in human omental and subcutaneous adipose tissue. PLoS ONE 2009, 4, e4699. [CrossRef] [PubMed]
51. Pan, J.; Chen, H. Expression of miR-155 and miR-146a in patients with type 2 diabetes mellitus and its significance. Zhejiang Clin. Med. 2014, 16, 1042-1043.
52. Yang, S.; Zhao, J.; Chen, Y.; Lei, M. Biomarkers associated with ischemic stroke in diabetes mellitus patients. Cardiovasc. Toxicol. 2016, 16, 213-222. [CrossRef] [PubMed]
53. Yan, S.; Wang, T.; Huang, S.; Di, Y.; Huang, Y.; Liu, X.; Luo, Z.; Han, W.; An, B. Differential expression of microRNAs in plasma of patients with prediabetes and newly diagnosed type 2 diabetes. Acta Diabetol. 2016, 53, 693-702. [CrossRef] [PubMed]
54. Wang, Y.; Li, J.Y.; Du, W.P.; Jin, W.B. Association analysis between plasma leptin, insulin levels and their microRNA expression in patients with type 2 diabetes mellitus. Chin. J. Diabetes 2016, 24, 28-31.
55. Wang, C.; Wan, S.; Yang, T.; Niu, D.; Zhang, A.; Yang, C.; Cai, J.; Wu, J.; Song, J.; Zhang, C.Y.; et al. Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus. Sci. Rep. 2016, 6, 20032. [CrossRef] [PubMed]
56. Seyhan, A.A.; Nunez Lopez, Y.O.; Xie, H.; Yi, F.; Mathews, C.; Pasarica, M.; Pratley, R.E. Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: A pilot cross-sectional study. Sci. Rep. 2016, 6, 31479. [CrossRef] [PubMed]
57. Rezk, N.A.; Sabbah, N.A.; Saad, M.S. Role of microRNA 126 in screening, diagnosis, and prognosis of diabetic patients in Egypt. IUBMB Life 2016, 68, 452-458. [CrossRef] [PubMed]
58. Pek, S.L.; Sum, C.F.; Lin, M.X.; Cheng, A.K.; Wong, M.T.; Lim, S.C.; Tavintharan, S. Circulating and visceral adipose miR-100 is down-regulated in patients with obesity and type 2 diabetes. Mol. Cell. Endocrinol. 2016, 427, 112-123. [CrossRef] [PubMed]
59. Li, M.Y.; Pan, S.R.; Qiu, A.Y. Roles of microRNA-221/222 in type 2 diabetic patients with post-menopausal breast cancer. Genet. Mol. Res. 2016. [CrossRef] [PubMed]
60. Latouche, C.; Natoli, A.; Reddy-Luthmoodoo, M.; Heywood, S.E.; Armitage, J.A.; Kingwell, B.A. MicroRNA-194 modulates glucose metabolism and its skeletal muscle expression is reduced in diabetes. PLoS ONE 2016, 11, e0155108. [CrossRef] [PubMed]
61. Jansen, F.; Wang, H.; Przybilla, D.; Franklin, B.S.; Dolf, A.; Pfeifer, P.; Schmitz, T.; Flender, A.; Endl, E.; Nickenig, G.; et al. Vascular endothelial microparticles-incorporated microRNAs are altered in patients with diabetes mellitus. Cardiovasc. Diabetol. 2016, 15, 49. [CrossRef] [PubMed]
62. Hou, X.; Wu, W.; Yin, B.; Liu, X.; Ren, F. MicroRNA-463-3p/ABCG4: A new axis in glucose-stimulated insulin secretion. Obesity 2016, 24, 2368-2376. [CrossRef] [PubMed]
63. Ding, L.; Ai, D.; Wu, R.; Zhang, T.; Jing, L.; Lu, J.; Zhong, L. Identification of the differential expression of serum microRNA in type 2 diabetes. Biosci. Biotechnol. Biochem. 2016, 80, 461-465. [CrossRef] [PubMed]
64. Baldeon Rojas, L.; Weigelt, K.; de Wit, H.; Ozcan, B.; van Oudenaren, A.; Sempertegui, F.; Sijbrands, E.; Grosse, L.; van Zonneveld, A.J.; Drexhage, H.A.; et al. Study on inflammation-related genes and microRNAs, with special emphasis on the vascular repair factor HGF andmiR-574-3p, in monocytes and serum of patients with T2D. Diabetol. Metab. Syndr. 2016, 8, 6. [CrossRef] [PubMed]
65. Sebastiani, G.; Po, A.; Miele, E.; Ventriglia, G.; Ceccarelli, E.; Bugliani, M.; Marselli, L.; Marchetti, P.; Gulino, A.; Ferretti, E.; et al. MicroRNA-124a is hyperexpressed in type 2 diabetic human pancreatic islets and negatively regulates insulin secretion. Acta Diabetol. 2015, 52, 523-530. [CrossRef] [PubMed]
66. Olivieri, F.; Spazzafumo, L.; Bonafe, M.; Recchioni, R.; Prattichizzo, F.; Marcheselli, F.; Micolucci, L.; Mensa, E.; Giuliani, A.; Santini, G.; et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: Relationship with type 2 diabetes complications. Oncotarget 2015, 6, 35372-35382. [PubMed]
67. Long, Y.; Zhan, Q.; Yuan, M.; Duan, X.; Zhou, J.; Lu, J.; Li, Z.; Yu, F.; Zhou, X.; Yang, Q.; et al. The expression of microRNA-223 and FAM5C in cerebral infarction patients with diabetes mellitus. Cardiovasc. Toxicol. 2017, 17, 42-48. [CrossRef] [PubMed]
68. Lenin, R.; Sankaramoorthy, A.; Mohan, V.; Balasubramanyam, M. Altered immunometabolism at the interface of increased endoplasmic reticulum (ER) stress in patients with type 2 diabetes. J. Leukoc. Biol. 2015, 98, 615-622. [CrossRef] [PubMed]
69. Jiao, Y.; Zhu, M.; Mao, X.; Long, M.; Du, X.; Wu, Y.; Abudureyimu, K.; Zhang, C.; Wang, Y.; Tao, Y.; et al. MicroRNA-130a expression is decreased in Xinjiang Uygur patients with type 2 diabetes mellitus. Am. J. Transl. Res. 2015, 7, 1984-1991. [PubMed]
70. Higuchi, C.; Nakatsuka, A.; Eguchi, J.; Teshigawara, S.; Kanzaki, M.; Katayama, A.; Yamaguchi, S.; Takahashi, N.; Murakami, K.; Ogawa, D.; et al. Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes. Metabolism 2015, 64, 489-497. [CrossRef] [PubMed]
71. Bao, L.; Fu, X.; Si, M.; Wang, Y.; Ma, R.; Ren, X.; Lv, H. MicroRNA-185 targets SOCS3 to inhibit β-cell dysfunction in diabetes. PLoS ONE 2015, 10, e0116067. [CrossRef] [PubMed]
72. Baldeon Rojas, L.; Weigelt, K.; de Wit, H.; Ozcan, B.; van Oudenaren, A.; Sempertegui, F.; Sijbrands, E.; Grosse, L.; van Zonneveld, A.J.; Drexhage, H.A.; et al. Type 2 diabetes monocyte microRNA and mRNA expression: Dyslipidemia associates with increased differentiation-related genes but not inflammatory activation. PLoS ONE 2015, 10, e0129421.
73. Al-Kafaji, G.; Al-Mahroos, G.; Alsayed, N.A.; Hasan, Z.A.; Nawaz, S.; Bakhiet, M. Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes. Mol. Med. Rep. 2015, 12, 7485-7490. [CrossRef] [PubMed]
74. Kong, L.; Han, W.X.; Jiang, X.Y.; AXu, J.; Zhang, X.; Li, Q.; Guan, Q.B.; Gao, L.; Zhao, J.J. Expression and clinical significance of peripheral miR-34a during the onset of type 2 diabetes. J. Shandong Univ. 2010, 48, 1-3.
75. Liang, G.W.; Song, Y.; Shao, D.H.; Xu, X.; He, M.L. The change of serum miR-375 and miR-29a and their correlation with glycemic control and lipid profile in patients with newly diagnosed type 2 diabete. Chin. J. Lab. Diagn. 2013, 17, 475-478.
76. Lu, S.Y.; Lu, Z.H.; Tan, L.; Wan, S. Association of Plasma miR-375 and miR-126 in patients with type 2 diabetes mellitus. J. Mod. Lab. Med. 2014, 29, 18-21.
77. Ortega, F.J.; Mercader, J.M.; Moreno-Navarrete, J.M.; Rovira, O.; Guerra, E.; Esteve, E.; Xifra, G.; Martinez, C.; Ricart, W.; Rieusset, J.; et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care 2014, 37, 1375-1383. [CrossRef] [PubMed]
78. Wang, X.; Sundquist, J.; Zoller, B.; Memon, A.A.; Palmer, K.; Sundquist, K.; Bennet, L. Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2. PLoS ONE 2014, 9, e86792. [CrossRef] [PubMed]
79. Wu, B.; Liu, W.-W.; HE, Y.; Hu, Y.S.; Zhang, Z.L. Analysis on related metabolic influencing factors for miR-21 expression levels in type 2 diabetic patients. Mod. Prev. Med. 2015, 42, 2218-2222.
80. Yan, S.T.; Li, C.L.; Tian, H.; Li, J.; Pei, Y.; Liu, Y.; Gong, Y.P.; Fang, F.S.; Sun, B.R. MiR-199a is overexpressed in plasma of type 2 diabetes patients which contributes to type 2 diabetes by targeting GLUT4. Mol. Cell. Biochem. 2014, 397, 45-51. [CrossRef] [PubMed]
81. Zhou, B.; Li, C.; Qi, W.; Zhang, Y.; Zhang, F.; Wu, J.X.; Hu, Y.N.; Wu, D.M.; Liu, Y.; Yan, T.T.; et al. Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 2012, 55, 2032-2043. [CrossRef] [PubMed]
82. Berends, L.; Ozanne, S. Early determinants of type-2 diabetes. Best Pract. Res. Clin. Endocrinol. Metabol. 2012, 26, 569-580. [CrossRef] [PubMed]
83. Lorenzen, J.; Kumarswamy, R.; Dangwal, S.; Thum, T. MicroRNAs in diabetes and diabetes-associated complications. RNA Biol. 2012, 9, 820-827. [CrossRef] [PubMed]
84. Dehwah, M.A.S.; Xu, A.; Huang, Q. MicroRNAs and type 2 diabetes/obesity. J. Genet. Genom. 2012, 39, 11-18. [CrossRef] [PubMed]
85. Rome, S. Are extracellular microRNAs involved in type 2 diabetes and related pathologies? Clin. Biochem. 2013, 46, 937-945. [CrossRef] [PubMed]
86. Pansuria, M.; Xi, H.; Li, L.; Yang, X.-F.; Wang, H. Insulin resistance, metabolic stress, and atherosclerosis. Front. Biosci. 2012, 4, 916-931.
87. Poy, M.N.; Eliasson, L.; Krutzfeldt, J.; Kuwajima, S.; Ma, X.; MacDonald, P.E.; Pfeffer, S.; Tuschl, T.; Rajewsky, N.; Rorsman, P. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004, 432, 226-230. [CrossRef] [PubMed]
88. Hashimoto, N.; Kido, Y.; Uchida, T.; Asahara, S.-I.; Shigeyama, Y.; Matsuda, T.; Takeda, A.; Tsuchihashi, D.; Nishizawa, A.; Ogawa, W. Ablation of PDK1 in pancreatic β-cells induces diabetes as a result of loss of β-cell mass. Nat. Genet. 2006, 38, 589-593. [CrossRef] [PubMed]
89. Gilbert, E.R.; Liu, D. Epigenetics: The missing link to understanding β-cell dysfunction in the pathogenesis of type 2 diabetes. Epigenetics 2012, 7, 841-852. [CrossRef] [PubMed]
90. Plaisance, V.; Waeber, G.; Regazzi, R.; Abderrahmani, A. Role of microRNAs in Islet β-cell compensation and failure during diabetes. J. Diabetes Res. 2014, 2014, 618652. [CrossRef] [PubMed]
91. Nesca, V.; Guay, C.; Jacovetti, C.; Menoud, V.; Peyot, M.-L.; Laybutt, D.R.; Prentki, M.; Regazzi, R. Identification of particular groups of microRNAs that positively or negatively impact on β-cell function in obese models of type 2 diabetes. Diabetologia 2013, 56, 2203-2212. [CrossRef] [PubMed]
92. Sacco, J.; Adeli, K. MicroRNAs: Emerging roles in lipid and lipoprotein metabolism. Curr. Opin. Lipidol. 2012, 23, 220-225. [CrossRef] [PubMed]
93. Williams, M.D.; Mitchell, G.M. MicroRNAs in insulin resistance and obesity. Exp. Diabetes Res. 2012, 2012, 484696. [CrossRef] [PubMed]
94. Karbiener, M.; Fischer, C.; Nowitsch, S.; Opriessnig, P.; Papak, C.; Ailhaud, G.; Dani, C.; Amri, E.-Z.; Scheideler, M. MicroRNA miR-27b impairs human adipocyte differentiation and targets PPAR. Biochem. Biophys. Res. Commun. 2009, 390, 247-251. [CrossRef] [PubMed]
95. Peng, Y.; Yu, S.; Li, H.; Xiang, H.; Peng, J.; Jiang, S. MicroRNAs: Emerging roles in adipogenesis and obesity. Cell. Signal. 2014, 26, 1888-1896. [CrossRef] [PubMed]
96. Hamar, P. Role of regulatory microRNAs in type 2 diabetes mellitus-related inflammation. Nucleic Acid Ther. 2012, 22, 289-294. [PubMed]
97. Keren, A.; Tamir, Y.; Bengal, E. The p38 MAPK signaling pathway: A major regulator of skeletal muscle development. Mol. Cell. Endocrinol. 2006, 252, 224-230. [CrossRef] [PubMed]
98. Song, M.-Y.; Pan, K.-F.; Su, H.-J.; Zhang, L.; Ma, J.-L.; Li, J.-Y.; Yuasa, Y.; Kang, D.; Kim, Y.S.; You, W.-C. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS ONE 2012, 7, e33608. [CrossRef] [PubMed]
99. Pan, F.; You, J.; Liu, Y.; Qiu, X.; Yu, W.; Ma, J.; Pan, L.; Zhang, A.; Zhang, Q. Differentially expressed microRNAs in the corpus cavernosum from a murine model with type 2 diabetes mellitus-associated erectile dysfunction. Mol. Genet. Genom. 2016, 291, 2215-2224. [CrossRef] [PubMed]
100. He, J.S.; Lian, C.W.; Fang, Y.L.; Wu, J.Z.; Ye, X.L.; Zhu, S.B. Influence and significance of intervening diabetes microRNA expression profile of NOD mice with exendin-4. Eur Rev. Med. Pharmacol. Sci. 2016, 20, 4322-4327. [PubMed]
101. Singh, G.B.; Raut, S.K.; Khanna, S.; Kumar, A.; Sharma, S.; Prasad, R.; Khullar, M. MicroRNA-200c modulates DUSP-1 expression in diabetes-induced cardiac hypertrophy. Mol. Cell. Biochem. 2016, 424, 1-11. [CrossRef] [PubMed]
102. Wei, S.; Zhang, M.; Yu, Y.; Xue, H.; Lan, X.; Liu, S.; Hatch, G.; Chen, L. HNF-4α regulated miR-122 contributes to development of gluconeogenesis and lipid metabolism disorders in type 2 diabetic mice and in palmitate-treated HepG2 cells. Eur. J. Pharmacol. 2016, 791, 254-263. [CrossRef] [PubMed]
103. Chen, H.Y.; Zhong, X.; Huang, X.R.; Meng, X.M.; You, Y.; Chung, A.C.; Lan, H.Y. MicroRNA-29b inhibits diabetic nephropathy in db/db mice. Mol. Ther. 2014, 22, 842-853. [CrossRef] [PubMed]
104. Guay, C.; Regazzi, R. Role of islet microRNAs in diabetes: Which model for which question? Diabetologia 2015, 58, 456-463. [CrossRef] [PubMed]
105. Huang, B.; Qin, W.; Zhao, B.; Shi, Y.; Yao, C.; Li, J.; Xiao, H.; Jin, Y. MicroRNA expression profiling in diabetic GK rat model. Acta Biochim. Biophys. Sin. 2009, 41, 472-477. [CrossRef] [PubMed]
106. Lu, T.P.; Lee, C.Y.; Tsai, M.H.; Chiu, Y.C.; Hsiao, C.K.; Lai, L.C.; Chuang, E.Y. MiRSystem: An integrated system for characterizing enriched functions and pathways of microRNA targets. PLoS ONE 2012, 7, e42390. [CrossRef] [PubMed]
107. Cho, S.; Jang, I.; Jun, Y.; Yoon, S.; Ko, M.; Kwon, Y.; Choi, I.; Chang, H.; Ryu, D.; Lee, B.; et al. MiRGator v3.0: A microRNA portal for deep sequencing, expression profiling and mRNA targeting. Nucleic Acids Res. 2013, 41, 252-257. [CrossRef] [PubMed]
108. Backes, C.; Kehl, T.; Stockel, D.; Fehlmann, T.; Schneider, L.; Meese, E.; Lenhof, H.P.; Keller, A. MiRPathDB: A new dictionary on microRNAs and target pathways. Nucleic Acids Res. 2017, 45, D90-D96. [CrossRef] [PubMed]
109. Palmer, J.D.; Soule, B.P.; Simone, B.A.; Zaorsky, N.G.; Jin, L.; Simone, N.L. MicroRNA expression altered by diet: Can food be medicinal? Ageing Res. Rev. 2014, 17, 16-24. [CrossRef] [PubMed]
110. Chen, G.Q.; Lian, W.J.; Wang, G.M.; Wang, S.; Yang, Y.Q.; Zhao, Z.W. Altered microRNA expression in skeletal muscle results from high-fat diet-induced insulin resistance in mice. Mol. Med. Rep. 2012, 5, 1362-1368. [PubMed]
111. Baier, S.R.; Nguyen, C.; Xie, F.; Wood, J.R.; Zempleni, J. MicroRNAs are absorbed in biologically meaningful amounts from nutritionally relevant doses of cow milk and affect gene expression in peripheral blood mononuclear cells, HEK-293 kidney cell cultures, and mouse livers. J. Nutr. 2014, 144, 1495-1500. [CrossRef] [PubMed]